Gain Therapeutics (NASDAQ:GANX) Earns Buy Rating from HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $8.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 236.13% from the company’s previous close.

A number of other equities analysts also recently issued reports on the company. Roth Mkm restated a “buy” rating and issued a $7.00 price target on shares of Gain Therapeutics in a research note on Tuesday, December 24th. Roth Capital upgraded Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Finally, Scotiabank began coverage on Gain Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $8.20.

Gain Therapeutics Stock Performance

GANX stock opened at $2.38 on Monday. The company has a market cap of $63.13 million, a P/E ratio of -2.16 and a beta of 0.14. Gain Therapeutics has a 1 year low of $0.89 and a 1 year high of $4.63. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. The stock’s fifty day moving average price is $2.23 and its 200-day moving average price is $2.01.

Hedge Funds Weigh In On Gain Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bridgeway Capital Management LLC purchased a new position in Gain Therapeutics during the fourth quarter valued at $65,000. Northern Trust Corp raised its holdings in Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after acquiring an additional 39,642 shares during the period. Marshall Wace LLP bought a new stake in Gain Therapeutics during the fourth quarter valued at about $198,000. Jones Financial Companies Lllp raised its holdings in Gain Therapeutics by 83.6% during the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after acquiring an additional 44,750 shares during the period. Finally, Sprott Inc. bought a new stake in Gain Therapeutics during the fourth quarter valued at about $30,000. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.